Are you Dr. Kim?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 44 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3601 The Vanderbilt Clinic
Nashville, TN 37232Phone+1 615-936-2000
Summary
- Dr. Dong Kim, MD is a radiation oncologist in Nashville, Tennessee. He is currently licensed to practice medicine in Tennessee, Massachusetts, and Texas. He is affiliated with Vanderbilt University Medical Center and is an Assistant Professor at University of Texas Southwestern Medical Center.
Education & Training
- Vanderbilt University Medical CenterResidency, Radiation Oncology, 2002 - 2006
- Vanderbilt University Medical CenterInternship, Internal Medicine, 2001 - 2002
- Boston University School of MedicineClass of 2001
Certifications & Licensure
- MO State Medical License 2006 - 2025
- TN State Medical License 2022 - 2025
- TX State Medical License 2007 - 2025
- MA State Medical License 2011 - 2017
- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer Start of enrollment: 2012 May 01
Publications & Presentations
PubMed
- Aspirin Use Is Associated With Improved Outcomes in Inflammatory Breast Cancer Patients.Christopher Johns, Allen Yen, Asal Rahimi, Yu-Lun Liu, Ann Marilyn Leitch
Journal of Breast Cancer. 2023-02-01 - 19 citationsA Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer.Michael R. Folkert, Michael J. Zelefsky, Raquibul Hannan, Neil Desai, Yair Lotan
International Journal of Radiation Oncology, Biology, Physics. 2021-09-01 - 12 citationsCosmetic Outcomes of a Phase 1 Dose Escalation Study of 5-Fraction Stereotactic Partial Breast Irradiation for Early Stage Breast Cancer.Asal Rahimi, Howard E. Morgan, Dong W. Kim, Yuanyuan Zhang, Marilyn Leitch
International Journal of Radiation Oncology, Biology, Physics. 2021-07-01